MP101

AXP000236.1 · Phage therapy

Platform
phage product (non-engineered)
Originator
MicrobiotiX
Sponsor
MicrobiotiX

Names

NameTypeSource
MP101preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Pseudomonas aeruginosa bacteriophage
Replication
replicating
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07492771MP101 in Adults With Acute Pseudomonas Aeruginosa PneumoniaRecruitingPhase 12026-07-252026-1218Pneumonia - Bacterial; Pseudomonas Aeruginosa Infection
NCT04922918Ligilactobacillus Salivarius MP101 for Elderly in a Nursing HomeUnknown2020-10-012021-06-2425Covid19
NCT03044249A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and AggressionTerminatedPhase 22017-05-042020-01-3081Aggression; Agitation; Alzheimer Dementia; Dementia; Psychosis
NCT02246816A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001WithdrawnPhase 32015-022018-020SBS; Short Bowel Syndrome; Short Gut; Short Gut Syndrome
NCT02242656A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-DiarrhealsWithdrawnPhase 32014-122017-120SBS; Short Bowel; Short Bowel Syndrome; Short Gut; Short Gut Syndrome
NCT00449254Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese AdultsUnknownPhase 22006-1024Obesity
NCT00449202Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)UnknownPhase 22006-06100Obesity

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 36552791Pharmacological Profile of MP-101, a Novel Non-racemic Mixture of R- and S-dimiracetam with Increased Potency in Rat Models of Cognition, Depression and Neuropathic Pain.Cells2022name in title: MP101
PMID 36590434Administration of Ligilactobacillus salivarius CECT 30632 to elderly during the COVID-19 pandemic: Nasal and fecal metataxonomic analysis and fatty acid profiling.Frontiers in microbiology2022name in abstract: MP101
PMID 34574259Administration of Ligilactobacillus salivarius MP101 in an Elderly Nursing Home during the COVID-19 Pandemic: Immunological and Nutritional Impact.Foods (Basel, Switzerland)2021name in title: MP101
PMID 31585135Disease modifying mitochondrial uncouplers, MP101, and a slow release ProDrug, MP201, in models of Multiple Sclerosis.Neurochemistry international2019name in title: MP101
PMID 18312263The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover.Molecular microbiology2008name in abstract: MP101
PMID 12701147Novel escherichia coli strain allows efficient recombinant protein production using lactose as inducer.Biotechnology and bioengineering2003name in abstract: MP101

Notes

Anti-Pseudomonas aeruginosa phage product in a phase 1 trial in acute P. aeruginosa pneumonia (NCT07492771).

How to cite

MP101 (AXP000236.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000236.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.